Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RCUS 
Arcus Biosciences Inc (RCUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: RCUS (1-star) is a SELL. SELL since 2 days. Profits (-12.92%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $28.18
1 Year Target Price $28.18
| 8 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.09% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 861.90M USD | Price to earnings Ratio - | 1Y Target Price 28.18 |
Price to earnings Ratio - | 1Y Target Price 28.18 | ||
Volume (30-day avg) 13 | Beta 0.83 | 52 Weeks Range 6.50 - 18.98 | Updated Date 06/30/2025 |
52 Weeks Range 6.50 - 18.98 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -277.3% | Operating Margin (TTM) -435.71% |
Management Effectiveness
Return on Assets (TTM) -22.25% | Return on Equity (TTM) -63.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -75094977 | Price to Sales(TTM) 6.11 |
Enterprise Value -75094977 | Price to Sales(TTM) 6.11 | ||
Enterprise Value to Revenue 2.34 | Enterprise Value to EBITDA 3.96 | Shares Outstanding 105885000 | Shares Floating 59724512 |
Shares Outstanding 105885000 | Shares Floating 59724512 | ||
Percent Insiders 34.93 | Percent Institutions 65.02 |
Analyst Ratings
Rating 4 | Target Price 28.18 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Arcus Biosciences Inc
Company Overview
History and Background
Arcus Biosciences Inc. was founded in 2015. It's a clinical-stage biopharmaceutical company focused on creating differentiated cancer therapies. The company has rapidly advanced multiple programs into clinical development through strategic collaborations and internal research.
Core Business Areas
- Small Molecule Therapeutics: Discovery and development of novel small molecule inhibitors targeting cancer-relevant pathways.
- Antibody Therapeutics: Development of antibodies designed to enhance the immune system's ability to fight cancer.
- Combination Therapies: Focus on creating combination therapies involving multiple mechanisms of action to improve patient outcomes.
Leadership and Structure
The leadership team includes Terry Rosen (CEO), Jennifer Doudna (Scientific Advisory Board). The organizational structure is typical of a biotech company, with departments focusing on research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Domvanalimab (anti-TIGIT antibody): Domvanalimab is Arcus's lead investigational TIGIT antibody, being evaluated in multiple clinical trials in combination with other therapies for various cancers. Market share data not yet available as it is not yet approved. Competitors include Roche (tiragolumab) and other companies developing anti-TIGIT antibodies.
- Etrilimus (adenosine receptor antagonist): Etrilimus, an A2a/A2b adenosine receptor antagonist, designed to reverse adenosine-mediated immunosuppression in the tumor microenvironment. Competitors include companies developing other adenosine pathway inhibitors.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by an aging population and advancements in cancer diagnostics and treatment. Immunotherapy is a major area of focus.
Positioning
Arcus Biosciences is positioned as a company focusing on novel combination therapies to improve cancer treatment outcomes. Its competitive advantage lies in its robust pipeline and strategic partnerships.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Arcus is positioned to capture a significant share through its innovative combination therapies. The oncology drug market is estimated at $200+ billion. Arcus seeks to access a substantial portion through targeted therapies and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong pipeline of novel cancer therapies
- Strategic partnerships with leading pharmaceutical companies
- Experienced management team
- Focus on innovative combination therapies
Weaknesses
- Limited commercial experience
- Dependence on collaborations for funding and development
- Clinical trial risk and regulatory hurdles
- Pipeline is not yet commercialized
Opportunities
- Expansion of pipeline through internal research and acquisitions
- Potential for breakthrough therapies in areas of unmet medical need
- Increased adoption of immunotherapy in cancer treatment
- Strategic partnership opportunities to drive growth
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles and changes
- Pricing pressures and reimbursement challenges
Competitors and Market Share
Key Competitors
- ROCHE HLDG AG (RHHBY)
- BRISTOL-MYERS SQUIBB (BMY)
- MERCK & CO (MRK)
- ASTRAZENECA PLC (AZN)
Competitive Landscape
Arcus faces competition from larger pharmaceutical companies with established oncology franchises. Arcus differentiates itself through its focus on novel combination therapies and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Arcus has experienced growth through pipeline expansion and strategic collaborations. Historical revenue growth is tied to milestone payments from partnerships.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst projections vary based on pipeline progress and market potential.
Recent Initiatives: Recent initiatives include advancing key clinical trials (e.g., Domvanalimab combination studies) and expanding partnerships with larger pharmaceutical companies.
Summary
Arcus Biosciences is a promising biotech company with a strong pipeline of novel cancer therapies and strategic partnerships. Its dependence on collaborations and clinical trial success pose risks. The company needs to demonstrate clinical efficacy and secure regulatory approvals to realize its full potential. Continued focus on innovative combination therapies and strategic partnerships could drive growth. Watch for potential partnerships with established players in the immunotherapy market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcus Biosciences Investor Relations
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be made based on individual financial circumstances and consultation with a qualified financial advisor. Market share data is approximate and based on available information. Clinical trial outcomes are inherently uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcus Biosciences Inc
Exchange NYSE | Headquaters Hayward, CA, United States | ||
IPO Launch date 2018-03-15 | Co-Founder, Chairman & CEO Dr. Terry J. Rosen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 627 | Website https://www.arcusbio.com |
Full time employees 627 | Website https://www.arcusbio.com | ||
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.